PRODUCT INFORMATION

LMB763

Item No. 30184



CAS Registry No.: 1773489-72-7
Formal Name: 4-[[[(8-chloro-1,4-dihydro-1-methyl[1]benzopyrano[4,3-c]pyrazol-3-yl)carbonyl](phenylmethyl)amino]methyl]-benzoic acid
Synonym: Nidufexor
MF: $C_{27}H_{22}ClN_3O_4$
FW: 487.9
Purity: ≥98%
UV/Vis.: λ_{max}: 232 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LMB763 is supplied as a solid. A stock solution may be made by dissolving the LMB763 in the solvent of choice, which should be purged with an inert gas. LMB763 is soluble in organic solvents such as ethanol and DMSO.

Description

LMB763 is a partial agonist of the farnesoid X receptor (FXR; EC_{50} = 7 nM).[1] It is selective for FXR over a panel of enzymes, ion channels, nuclear receptors, and G protein-coupled receptors, including the androgen receptor, estrogen receptor α (ERα), and G protein-coupled bile acid receptor 1 (GPBAR1; EC_{50}s = >30, >30, and >80 µM, respectively). LMB763 induces expression of the FXR target genes encoding the bile salt export pump and short heterodimer partner in isolated rat hepatocytes in a concentration-dependent manner. It decreases non-alcoholic fatty liver disease (NAFLD) scores and liver fibrosis in a rat model of non-alcoholic steatohepatitis (NASH).

Reference

1. Chianelli, D., Rucker, P.V., Roland, J., *et al.* Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis (NASH). *J. Med. Chem.* **63(8)**, 3868-3880 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM